FOXJ2 and Obesity: Moreover, a reduction in Foxj2 levels was observed during the pathological processes of numerous diseases characterized by inflammation, including high‐fat diet (HFD)–induced obesity, HFD‐induced nonalcoholic fatty liver disease (NAFLD), doxorubicin‐induced cardiomyopathy, acute myocardial infarction (AMI) and D‐galactose induced aging conditions.